SCHEMBL21991986

SCHEMBL21991986

CCOC(=O)C(C)(C)CCOc1ccc(Cl)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 2/20 0.60
ABCB11 O95342 2/20 0.60
CYP1A2 P05177 2/20 0.60
CYP3A4 P08684 2/20 0.60
PMP22 Q01453 2/20 0.60
TSHR P16473 1/20 0.60
HTR2A P28223 1/20 0.60
OPRK1 P41145 1/20 0.51
MAPT P10636 2/20 0.47
LMNA P02545 1/20 0.47
MAPK1 P28482 1/20 0.47
HRH2 P25021 1/20 0.46
HRH1 P35367 1/20 0.46
CYP2C19 P33261 1/20 0.46
BLM P54132 1/20 0.45
ALDH1A1 P00352 2/20 0.44
NPC1 O15118 2/20 0.44
MAOB P27338 1/20 0.44
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21991360 0.96 PPARA (0.56) PPARAABCB11CYP1A2CYP3A4PMP22
SCHEMBL21991354 0.93 PPARA (0.53) PPARAABCB11CYP1A2CYP3A4PMP22
SCHEMBL21992733 0.92 MAOB (0.52) PPARAABCB11CYP1A2CYP3A4PMP22
SCHEMBL21991961 0.88 L3MBTL1 (0.51) PPARAABCB11CYP1A2CYP3A4PMP22
SCHEMBL21991979 0.87 PPARA (0.50) PPARAABCB11CYP1A2CYP3A4PMP22
SCHEMBL21991575 0.85 CYP1A2 (0.45) PPARAABCB11CYP1A2CYP3A4PMP22
SCHEMBL21991351 0.85 HRH2 (0.46) PPARAABCB11CYP1A2CYP3A4PMP22
SCHEMBL21991541 0.85 PPARA (0.63) PPARAABCB11CYP1A2CYP3A4PMP22
SCHEMBL21991577 0.85 PPARA (0.53) PPARAABCB11CYP1A2CYP3A4PMP22
SCHEMBL21992682 0.81 PPARA (0.72) PPARACYP1A2CYP3A4MAPTCYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220409566-A1 CCL5 Inhibitors LAPKO INC, dba AFECTA PHARMACEUTICALS 2022-12-29 US disclosed
US-20220142961-A1 CCL5 Inhibitors LAPKO INC, dba AFECTA PHARMACEUTICALS 2022-05-12 US disclosed
US-11318111-B2 CCL5 inhibitors LAPKO INC (US) 2022-05-03 US disclosed
US-20210196665-A1 CCL5 Inhibitors AFECTA PHARMACEUTICALS, INC. (US) 2021-07-01 US disclosed
US-10940132-B2 CCL5 inhibitors AFECTA PHARMACEUTICALS, INC. (US) 2021-03-09 US disclosed
US-20200138766-A1 CCL5 INHIBITORS LAPKO INC. DBA AFECTA PHARMACEUTICALS 2020-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220142961-A1 CCL5 Inhibitors CCL5, CCL11, CCR5 PPARA 806/4885ABCB11 404/4885CYP1A2 2919/4885
US-20200138766-A1 CCL5 INHIBITORS CCL5, CCL11, CCR5 PPARA 806/4885ABCB11 404/4885CYP1A2 2919/4885
US-20210196665-A1 CCL5 Inhibitors CCL5, CCL11, CCR5 PPARA 806/4885ABCB11 404/4885CYP1A2 2919/4885
US-10940132-B2 CCL5 inhibitors CCL5, CCL11, CCR5 PPARA 806/4885ABCB11 404/4885CYP1A2 2919/4885
US-11318111-B2 CCL5 inhibitors CCL5, CCL11, CCR5 PPARA 806/4885ABCB11 404/4885CYP1A2 2919/4885
US-20220409566-A1 CCL5 Inhibitors CCL5, CCL11, CCR5 PPARA 806/4885ABCB11 404/4885CYP1A2 2919/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.